University of Queensland Partners with Molecule to Medicine to Boost Drug Discovery

By Kai November 14, 2024
Alarm 2 Min Read
Copied
Featured

The University of Queensland (UQ) has established a new partnership with global biotech firm Molecule to Medicine (MTM) to advance drug discovery and development. This collaboration aims to enhance UQ’s capabilities in creating innovative therapies, with an initial focus on diseases such as Alzheimer’s, Parkinson’s, and motor neurone disease.

UniQuest CEO Dr Dean Moss emphasised that MTM’s expertise in integrating the right people, funding, and technology will help accelerate the translation of UQ’s cutting-edge research into clinical applications. The partnership will be supported by investment from the UniQuest Extension Fund, further bridging the gap between research and patient treatment.

Dr Tom McCarthy, chairperson of MTM, expressed enthusiasm about strengthening the collaboration, highlighting UQ’s international reputation for research excellence. The partnership seeks to advance treatments, particularly in the area of neuroinflammation-related diseases, and bring them closer to clinical application.

In addition to its drug discovery efforts, UQ has announced the appointment of three academics as social science fellows, recognising their significant contributions to strategic management, social justice, and Indigenous studies.

Meanwhile, UQ’s virology team is collaborating with Vicebio to develop a new vaccine aimed at preventing respiratory illnesses caused by the RSV and hMPV viruses. Volunteer recruitment for clinical trials is currently underway, marking another milestone in the university’s healthcare innovations.

Source: SHIKSHA

More Articles